| Literature DB >> 32397264 |
Amanda Moyano1, Esther Serrano-Pertierra1, María Salvador2, José Carlos Martínez-García2, Montserrat Rivas2, M Carmen Blanco-López1.
Abstract
A new generation of magnetic lateral flow immunoassays is emerging as powerful tool for diagnostics. They rely on the use of magnetic nanoparticles (MNP) as detecting label, replacing conventional gold or latex beads. MNPs can be sensed and quantified by means of external devices, allowing the development of immunochromatographic tests with a quantitative capability. Moreover, they have an added advantage because they can be used for immunomagnetic separation (IMS), with improvements in selectivity and sensitivity. In this paper, we have reviewed the current knowledge on magnetic-lateral flow immunoassay (LFIA), coupled with both research and commercially available instruments. The work in the literature has been classified in two categories: optical and magnetic sensing. We have analysed the type of magnetic nanoparticles used in each case, their size, coating, crystal structure and the functional groups for their conjugation with biomolecules. We have also taken into account the analytical characteristics and the type of transduction. Magnetic LFIA have been used for the determination of biomarkers, pathogens, toxins, allergens and drugs. Nanocomposites have been developed as alternative to MNP with the purpose of sensitivity enhancement. Moreover, IMS in combination with other detection principles could also improve sensitivity and limit of detection. The critical analysis in this review could have an impact for the future development of magnetic LFIA in fields requiring both rapid separation and quantification.Entities:
Keywords: lateral flow immunoassay; magnetic biosensors; magnetic nanoparticles; magnetic transduction; nanocomposites; optical transduction
Year: 2020 PMID: 32397264 PMCID: PMC7278001 DOI: 10.3390/diagnostics10050288
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Summary of the basic formats of lateral flow assays. (A) Scheme of a sandwich format lateral flow immunoassays (LFIA). (B) Scheme of a competitive format LFIA: (1) when antigen is immobilized at the test line and labelled antibody is used as detection system; (2) when antibody is immobilized at the test line and labelled antigen is used for detection.
Figure 2Scheme of the immunomagnetic separation (IMS) procedure.
Characterization techniques and their corresponding information obtained for magnetic nanoparticles (MNPs).
| Techniques | Characterization Information |
|---|---|
| Microscopy: Transmission electron microscopy and Scanning electron microscopy | Morphology, size distribution, crystallinity and composition |
| X-ray diffraction (XRD) | Crystal structure and size |
| Dynamic light scattering (DLS) | Hydrodynamic size |
| Infrared spectroscopy (IR) | Nature of surface and functional groups on surface |
| Zeta potential | Surface charge and stability |
| Thermal analysis | Concentration and thermal stability |
| Mass spectroscopy | Concentration |
| Superconducting quantum interference device (SQUID)/Vibrating sample magnetometry (VSM) | Magnetic properties |
Figure 3Transmission electron microscopy images of magnetite nanoparticles. (A) Monodisperse MNP with spherical shape and (B) polydisperse nanoparticles with irregular spherical shape.
Figure 4Schematic representation of direct bond between gold@magnetic nanoparticles and proteins (A), covalent bond between gold@magnetic nanoparticles and proteins (B) and covalent bond between functionalized magnetic nanoparticles and proteins (C).
Figure 5Detection of magnetic nanoparticles used as labels in LFIA: (A) visual detection by naked eye. (B) Optical detection using smartphone with special software. (C) Magnetic quantification using magnetic transduction. (D) Advantages of magnetic detection over optical detection.
Type of magnetic nanoparticles used for each magnetic transducing principle.
| Transducing Principle | Nanoparticles | References |
|---|---|---|
|
| Superparamagnetic nanoparticles | [ |
| Superparamagnetic maghemite nanoparticles | [ | |
| Beads of 440 nm in diameter | [ | |
| Superparamagnetic Maghemite nanoparticles (200 nm) | [ | |
| Magnetic beads of 200 nm | [ | |
| Superparamagnetic nanoparticles (10.5 nm) | [ | |
| [ | ||
| Superparamagnetic nanoparticles (80 nm) | [ | |
|
| Superparamagnetic nanoparticles encapsulated in microspheres (198 nm) | [ |
| Paramagnetic particles (760 nm) | [ | |
| Superparamagnetic nanoparticles (50 nm) | [ | |
| Superparamagnetic nanoparticles encapsulated in microspheres (198 nm) | [ | |
| Magnetic nanobeads (15, 80 and 200 nm) | [ | |
| Superparamagnetic nanoparticles (140 nm) | [ | |
| Superparamagnetic nanoparticles (15 nm) | [ | |
| Superparamagnetic nanoparticles (140 nm) | [ | |
| Colorimetric-Fluorescent-Magnetic nanospheres (300 nm) | [ | |
| Superparamagnetic nanoparticles (10 nm) | [ | |
| Superparamagnetic nanoparticles (200 nm) | [ | |
| Superparamagnetic nanoparticles (10.5 nm) | [ | |
| Superparamagnetic magnetite nanoparticles | [ |
Figure 6(A) Schemes of a Giant Magnetoresistance (GMR) sensor (left), and a Tunnel Magnetoresistance (TMR) sensor (right). (B) Scheme of the resistance of the MR sensor as a function of the applied field (black line). The MNP’s magnetic moments align in the direction of the applied field, and their solenoidal magnetostatic field reduces the magnetization of the free layer (the magnetic field lines are represented as grey dashed lines.) In consequence, if the applied field is positive, the resistance of the sensor decreases, and if it is negative, the resistance increases (red line).
Figure 7Left: Scheme of the scanning inductive reader for magnetic LFIA. Right: Signal recorded for histamine competitive LFIA (blank sample, competitive immunoassay).
Most recent Magnetic LFIA with optical detection.
| Nanoparticles | Conjugation | Detection | Analyte | Limit of Detection | Reference |
|---|---|---|---|---|---|
|
| |||||
| Gold magnetic nanoparticles | Via Au–S bonds | Visual detection |
| 5 × 105 CFU/mL | [ |
| Gold magnetic nanoparticles | Via Au–S bonds | Colour intensity. ImageJ density analysis |
| 103 CFU/mL | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Colour intensity. TotalLab TL120 | Potato virus X | 0.5 ng/mL | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Colour intensity. TotalLab TL120 | Potato virus X | 0.25 ng/mL | [ |
| Gold magnetic nanoparticles | Via Au–S bonds | Visual detection | Avian influenza virus subtype H7 (AIV H7) | 103 5 EID50 | [ |
|
| |||||
| Gold magnetic nanoparticles | Via Au–S bonds | Visual detection | β-Conglutin | 8 fM | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Visual detection | Melamine | 0.4 ppm for Fe2O3PEG | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Visual detection | Furazolidone metabolite of 3-amino-2-oxazolidinone (AOZ) | 0.044 ng/mL | [ |
|
| |||||
| Magnetic nanoparticles | EDC chemistry | Visual detection | Carcinoembryonic antigen (CEA) | 0.25 ng/mL | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Reflectance measurements. ESE Quant LR3 (Qiagen Inc., Germany) | Extracellular vesicles (EVs) | 107 EVs/mL | [ |
| Gold magnetic nanoparticles | EDC chemistry | Visual detection | Genotyping of MTHFR C677T | 5 ng | [ |
| Gold magnetic nanoparticles | CTAB-PSS modification (direct bonds) | Visual detection | Genotype Apolipoprotein E | 10 ng | [ |
| Gold magnetic nanoparticles | EDC chemistry | Visual detection | IgM class antibodies related infections | - | [ |
| Magnetic nanoparticles | Periodate-based oxidation of the glycosylated Fc residues | Colour intensity. ImageJ density analysis | Human chorionic gonadotropin (hCG) | 0.31 ng/mL | [ |
|
| |||||
| Magnetic nanoparticles | EDC/NHS Chemistry | Smart phone camera was used for quantitative analysis | Cocaine | 5 ng/mL | [ |
Most recent Magnetic LFIA with magnetic detection.
| Nanoparticles | Conjugation | Detection | Analyte | Limit of Detection | Reference |
|---|---|---|---|---|---|
|
| |||||
| Magnetic nanoparticles | EDC/NHS Chemistry | MAR system (MagnaBioSciences, CA, USA) |
| 4.73 × 103 CFU/mL | [ |
| Colorimetric-Fluorescent-Magnetic nanoparticles | EDC/NHS Chemistry | MAR system (MagnaBioSciences, CA, USA) |
| 1.88 × 104 CFU/mL: naked detection | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Reader Miateks (Magnisense) |
| 105 cells/L | [ |
|
| |||||
| Magnetic nanoparticles | EDC/NHS Chemistry | Magnetic particle quantification (MPQ) method | Botulinum neurotoxin (BoNT) types A, B and E | 0.22 ng/mL for BoNT-A | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Novel sensor developed by authors | Histamine | 1.2 mg/L for magnetic sensor | [ |
|
| |||||
| Magnetic nanoparticles | EDC/NHS Chemistry | MAR system (MagnaBioSciences, CA, USA) | Carbohydrate antigen 72-4 (CA72-4) | 0.38 IU/mL | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Novel sensor developed by authors | Prostate-Specific Antigen | 0.25 ng/mL | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | MAR system (MagnaBioSciences, CA, USA) | Neuron specific enolase (NSE) | 0.094 ng/mL for NSE 0.045 ng/mL for CEA | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Magnetic particle quantification (MPQ) method | Thyroxine | 20 fM | [ |
| Magnetic nanoparticles | EDC Chemistry | MAR system (MagnaBioSciences, CA, USA) | Amino-terminal pro-B-type natriuretic peptide | 100 pg/mL | [ |
| Gold magnetic nanoparticles | EDC Chemistry | MAR system (MagnaBioSciences, CA, USA) | Single nucleotide polymorphisms (SNPs) | 0.04 pg/μL with plasmid | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | MIR system developed by authors | Troponin I (cTnI) | 0.0089 ng/mL for cTnI | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | MAR system (MagnaBioSciences, CA, USA) | Unconjugated estriol (uE3) | 0.86 nmol/L | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | MAR system (MagnaBioSciences, CA, USA) | D-dimer | 0.05 μg/mL | [ |
| Gold magnetic nanoparticles | - | Magnetic quantitative immunoanalyzer | C-reactive protein (CRP) | 0.15 mg/mL | [ |
Other detection and magnetic nanoparticles used for immunomagnetic separation.
| Nanoparticles | Conjugation | Detection | Analyte | Limit of Detection | Reference |
|---|---|---|---|---|---|
| Magnetic nanoparticles | Glutaraldehyde chemistry | Visual detection |
| 100 with pure culture | [ |
| Magnetic nanoparticles | Biotin-streptavidin affinity | Visual detection |
| 3.5 × 103 CFU/mL for standards | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Electrochemical detection. |
| 6.2 × 104 CFU/mL | [ |
| Gold magnetic nanoparticles | Via Au–S bonds | Visual detection | 23 CFU/mL for E. coli | [ | |
| Magnetic nanoparticles | Glutaraldehyde chemistry | Visual detection. |
| 102 CFU/mL | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Fluorescent detection |
| 104 CFU/mL | [ |
| Fluorescent magnetic nanoparticles | EDC chemistry | Fluorescent detection. Fluorescent strip reader (Suzhou Hemai Precision Instrument Co., Ltd. Jiangsu, China). | Aflatoxin B1 (AFB1) | 3 pg/mL in sauce extract | [ |
| Magnetic nanoparticles | EDC/NHS Chemistry | Electrochemical detection. | Phospho-p5315 | 50 pg/mL | [ |
Limit of detection improvements using IMS.
| Analyte | Limit of Detection Using LFIA | Limit of Detection Using LFIA in Combination with IMS | References |
|---|---|---|---|
|
| |||
|
| 105 cfu/mL for gold nanoparticles (pure culture) | 100 cfu/mL (pure culture) | [ |
|
| 104 cfu/mL for superparamagnetic nanoparticles | 3.5 × 103 cfu/mL (buffer) | [ |
| 23 CFU/mL for | [ | ||
|
| 0.25 ng/mL for combination of magnetic nanoparticles with gold nanoparticles | 8 ng/mL | [ |
|
| 103 cfu/mL for gold nanoparticles | 102 cfu/mL | [ |
| β-conglutin | 5 nM for gold nanoparticles | 8 fM | [ |
|
| |||
| Aflatoxin B1 | 10 µg/mL for gold nanoparticles | 3 pg/mL in sauce extract | [ |
|
| 3.7 × 106 cfu/mL for gold nanoparticles | 104 CFU/mL | [ |
|
| |||
|
| 105 cfu/mL for gold nanoparticles | 6.2 × 104 CFU/mL | [ |